Preparation of novel trivalent vaccine against enterotoxigenic Escherichia coli for preventing newborn piglet diarrhea
American Journal of Veterinary Research · 2023
DOI: 10.2460/ajvr.22.10.0183 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2023. Verfasst von ChongLi Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Medical Technology, Chongqing Medical and Pharmaceutical College, Chongqing, People's Republic of China. Hauptthemen laut MEDLINE: Bacterial Toxins, Enterotoxigenic Escherichia coli, Escherichia coli Infections, Escherichia coli Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE To develop a trivalent genetically engineered inactivated Escherichia coli vaccine (K88ac-3STa-LT B ) that neutralizes the STa toxin by targeting fimbriae and entertoxins for the treatment of enterotoxigenic E coli . ANIMALS 18- to 22-g mice, rabbits, pregnant sows. PROCEDURES Using PCR, the K88ac gene and LT B gene were cloned separately from the template C83902 plasmid. At the same time, the 3 STa mutant genes were also amplified by using the gene-directed mutation technology. Immune protection experiments were performed, and the minimum immune dose was determined in mice and pregnant sows. RESULTS The ELISA test could be recognized by the STa, LT B , and K88ac antibodies. Intragastric administration in the suckling mouse confirmed that the protein had lost the toxicity of the natural STa enterotoxin. The results of the immune experiments showed that K88ac-3STa-LT B protein could stimulate rabbits to produce serum antibodies and neutralize the toxicity of natural STa enterotoxin. The efficacy test of the K88ac-3STa-LT B -inactivated vaccine showed that the immune protection rate of the newborn piglets could reach 85% on the first day after suckling. At the same time, it was determined that the minimum immunization doses for mice and pregnant sows were 0.2 and 2.5 mL, respectively. CLINICAL RELEVANCE This research indicates that the K88ac-3STa-LT B trivalent genetically engineered inactivated vaccine provides a broad immune spectrum for E coli diarrhea in newborn piglets and prepares a new genetically engineered vaccine candidate strain for prevention of E coli diarrhea in piglets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Medical Technology, Chongqing Medical and Pharmaceutical College, Chongqing, People's Republic of China.
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, People's Republic of China.
- Henry Fok College of Biology and Agriculture, Shaoguan University, Shaoguan, People's Republic of China.
Zitieren
APA
Xu, C., Peng, K., She, Y., Fu, F., Shi, Q., Lin, Y., & Xu, C. (2023). Preparation of novel trivalent vaccine against enterotoxigenic Escherichia coli for preventing newborn piglet diarrhea. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.22.10.0183
Vancouver
Xu C, Peng K, She Y, Fu F, Shi Q, Lin Y, et al. Preparation of novel trivalent vaccine against enterotoxigenic Escherichia coli for preventing newborn piglet diarrhea. American Journal of Veterinary Research. 2023. doi:10.2460/ajvr.22.10.0183
BibTeX
@article{Xu2023,
author = {Xu, ChongLi and Peng, Kun and She, Yuhan and Fu, Fengyang and Shi, Qinhong and Lin, Yimin and Xu, ChongBo},
title = {Preparation of novel trivalent vaccine against enterotoxigenic Escherichia coli for preventing newborn piglet diarrhea},
journal = {American Journal of Veterinary Research},
year = {2023},
doi = {10.2460/ajvr.22.10.0183}
}
EUVIMED